Related Experiment Video

Updated: Jun 21, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

18.9K

Paltusotine: A Step Toward Precision Medicine in Acromegaly

Frederic Castinetti1, Thierry Brue1

  • 1Department of Endocrinology, Centre de Référence des Maladies Rares hypophysaires HYPO, Hôpital La Conception, Aix Marseille Univ, INSERM, UMR1251, Marseille Medical Genetics, Institut MarMaRa, and APHM, 13385 Marseille, France.

The Journal of Clinical Endocrinology and Metabolism
|July 15, 2024
PubMed
Summary

No abstract available in PubMed .

Keywords:
acromegalylanreotideoctreotidepituitarysomatostatin

More Related Videos

Adaptable Angled Stereotactic Approach for Versatile Neuroscience Techniques06:21

Adaptable Angled Stereotactic Approach for Versatile Neuroscience Techniques

Published on: May 7, 2020

5.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K